UNSPSC 51201539: Efalizumab

This classification denotes an immunomodulator, an immunosuppressant, and monoclonal antibody, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XX2MN88N5D. Most nations schedule Efalizumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, EFALIZUMAB remains the US FDA Preferred Term for this commodity.. Efalizumab bears US NLM identifiers UMLS ID C1320125 and NCI Concept Code C68831.

UNSPSC 51201539 Efalizumab, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity. Efalizumab is a biopharmaceutical product (a monoclonal antibody immunosuppressant), yet the three most recent opportunities tagged under this code—athletic training services for the City of Tucson Fire and Police Departments, medical aid supplies for the City of Tampa Fire Rescue Department, and a Request for Information from the Texas Health and Human Services Commission regarding direct-to-manufacturer prescription programs—do not involve the drug itself. The athletic training and medical aid supplies solicitations are services and supply management unrelated to pharmaceutical procurement, while the Texas HHS RFI addresses pharmacy benefit program logistics and contracting strategy rather than specific pharmaceutical products. No state or local government has recently solicited Efalizumab or pharmaceuticals substantially similar in scope under this code.

The geographic spread of recent activity spans Arizona (Tucson), Florida (Tampa), and Texas, but the opportunities reflect misclassification rather than genuine demand for the commodity. The City of Tucson RFP (Solicitation 260163) closed on June 9, 2026, seeking athletic trainers certified by NATA BOC and holding current Arizona licensure with a minimum three years' public safety experience; the City of Tampa ITB 25-P-00157 for medical aid supplies closed on April 9, 2025, with a $100,000 department budget and set-aside provisions for small local business enterprises and underutilized women and minority-owned businesses; and the Texas HHS Commission RFI HHS0017013 (posted April 3, 2026) gathered vendor intelligence on direct-to-manufacturer pharmacy contracting without specifying award values or formal evaluation criteria. The code appears dormant for its intended pharmaceutical scope at the state and local level.